Cogent Biosciences Stock (NASDAQ:COGT)
Previous Close
$4.87
52W Range
$3.72 - $12.61
50D Avg
$6.85
200D Avg
$8.94
Market Cap
$486.14M
Avg Vol (3M)
$1.43M
Beta
0.20
Div Yield
-
COGT Company Profile
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
COGT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| KALV | KalVista Pharmaceuticals, Inc. |
| IDYA | IDEAYA Biosciences, Inc. |
| MRSN | Mersana Therapeutics, Inc. |
| ZNTL | Zentalis Pharmaceuticals, Inc. |
| KNSA | Kiniksa Pharmaceuticals, Ltd. |
| MGTX | MeiraGTx Holdings plc |
| KURA | Kura Oncology, Inc. |
| VRNA | Verona Pharma plc |
| ANAB | AnaptysBio, Inc. |
| VTYX | Ventyx Biosciences, Inc. |
| SANA | Sana Biotechnology, Inc. |
| KROS | Keros Therapeutics, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| OLMA | Olema Pharmaceuticals, Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| PTGX | Protagonist Therapeutics, Inc. |